News & Updates
Filter by Specialty:

Dupilumab trumps MTX, cyclosporine in paediatric AD
03 Feb 2025
byStephen Padilla
The use of dupilumab in children with moderate-to-severe atopic dermatitis (AD) results in greater improvements in AD severity, better adherence, and fewer treatment-emergent adverse events (TEAEs) than methotrexate (MTX) or cyclosporine, as shown by 2-year interim results from the PEDISTAD study.
Dupilumab trumps MTX, cyclosporine in paediatric AD
03 Feb 2025
COVID-linked MIS-C outcomes reassuring at 6 months
31 Jan 2025
byElvira Manzano
Children and young adults with multisystem inflammatory syndrome in children (MIS-C) related to COVID-19 infection show good cardiovascular and noncardiovascular outcomes at 6 months, according to data from the long-term MUSIC study.